Bruins, D. , de Vroege, L. and van den Broek, A. (2026) The Mental Health of Mental Healthcare Professionals (MHCPs): A ...

ALX Oncology pivots to targeting HER2-positive underperformance in the intent-to-treat gastric cancer population. See why ...

Use the vitals package with ellmer to evaluate and compare the accuracy of LLMs, including writing evals to test local models ...

EMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges’ g = 0.45; p-value = 0.036, one ...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF ...

Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to ...

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...

Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company antici ...

Discover how AI is transforming nutritional science by turning complex diet and omics data into predictive tools that reshape chronic disease prevention and personalized care.

Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...

Artificial intelligence (AI) is rapidly transforming healthcare and medical education. From enhancing diagnostic accuracy and clinical decision-making to enabling virtual simulations and personalized ...